Figure 1. Anti-proliferative effects of combination treatment with anti-HER-2 (266–296) and anti-VEGF-P3 antibodies. (A-C) Inhibition of proliferation with individual anti-HER-2 and anti-VEGF- antibodies in two different cell-lines. BT474 (A) and MDA-468 (B) cells were incubated with HER-2 peptide antibodies, VEGF peptide antibodies, Trastuzumab and unspecific rabbit IgG. Bioconversion of MTT was used to estimate the number of active tumor cells remaining after 3 d. Peptides were added at four different concentrations. The proliferation inhibition rate was calculated using the formula (OD normal Untreated - OD peptides or antibodies)/OD normal untreated x 100. Error bars represent SD. Inhibition of proliferation of combination treatment with anti-HER-2 and anti-VEGF antipeptide antibodies using B-T474 cell lines (C). BT-474 cells were treated in the same manner as above but with HER-2 peptide abs, VEGF peptide abs or combination of both. Trastuzumab and rabbit IgG were used as positive and negative controls. Rate of inhibition was calculated using the same formula above and all results represents the average of three different experiments. Error bars represent SD of the mean.